AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$ANIX

Titterton Lewis H jr purchased $7K of ANIX

Titterton Lewis H jr purchased 2,836 shares of Anixa Biosciences Inc (ANIX) at $2.64 on 2026-06-16.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jun 17, 2026, 3:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 3:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
low confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value) disclosed on 2026-06-17 for a trade dated 2026-06-16.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new fundamentals or guidance.

03

What to watch

Check whether the director has a history of buys/sells and whether there are concurrent corporate events (financing, trial updates) not mentioned here.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17; transaction dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Anixa Biosciences (ANIX).

Company-level read

Ticker impact

$ANIXBullishLow confidence
Context

Anixa Biosciences director Titterton Lewis H jr filed a Form 4 open-market purchase of 2,836 shares at $2.6400 on 2026-06-16.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The disclosure is a routine Form 4 insider purchase with no new operational/financial catalyst, and the transaction size is small relative to typical market-moving thresholds.

Market effects

Sector

Minimal; single-company insider transaction without sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be discretionary and may not reflect a durable thesis; without a 10b5-1 plan, timing could be opportunistic rather than informational.

Key entities

  • issuer
    Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Titterton Lewis H jr

    Director who reported an open-market purchase of ANIX shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

OCT 6
$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

investing.com2 min
OCT 5
$ANIXMed

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

prnewswire.com2 min
OCT 1
$ANIXMedAI 8/10

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

prnewswire.com2 min
SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min